GLAXOSMITHKLINE PHARMA LT Financial Ratios
GLAXO · Healthcare · Current price ₹2,454.8
P/E ratio
40.1x
P/B ratio
18.3x
ROE
45.6%
ROCE
61.0%
Debt / Equity
0.01
Dividend yield
2.3%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 40.1x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 18.3x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 45.6% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 61.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.01 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with GLAXOSMITHKLINE PHARMA LT's latest numbers.
GLAXOSMITHKLINE PHARMA LT profitability
GLAXOSMITHKLINE PHARMA LT generates a return on equity of 45.6% and a return on capital employed of 61.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.01 and a P/E of 40.1x, GLAXOSMITHKLINE PHARMA LT is conservatively financed. Our overall business-quality score for the company is 5.9 / 10.
Understand the ratios
More on GLAXOSMITHKLINE PHARMA LT
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.